Echo Therapeutics (NASDAQ: ECTE) and Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitabiliy, institutional ownership, risk and valuation.

Volatility & Risk

Echo Therapeutics has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals Holding Corp. has a beta of 2.85, meaning that its stock price is 185% more volatile than the S&P 500.

Valuation & Earnings

This table compares Echo Therapeutics and Tonix Pharmaceuticals Holding Corp.’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Echo Therapeutics N/A N/A N/A ($1.48) -0.03
Tonix Pharmaceuticals Holding Corp. N/A N/A -$29.87 million ($11.25) -0.38

Tonix Pharmaceuticals Holding Corp. is trading at a lower price-to-earnings ratio than Echo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Echo Therapeutics and Tonix Pharmaceuticals Holding Corp.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Echo Therapeutics N/A N/A 216.11%
Tonix Pharmaceuticals Holding Corp. N/A -107.33% -97.16%

Institutional & Insider Ownership

17.5% of Tonix Pharmaceuticals Holding Corp. shares are held by institutional investors. 4.0% of Tonix Pharmaceuticals Holding Corp. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Echo Therapeutics and Tonix Pharmaceuticals Holding Corp., as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Echo Therapeutics 0 0 0 0 N/A
Tonix Pharmaceuticals Holding Corp. 0 3 1 0 2.25

Tonix Pharmaceuticals Holding Corp. has a consensus target price of $7.50, indicating a potential upside of 75.64%. Given Tonix Pharmaceuticals Holding Corp.’s higher possible upside, analysts clearly believe Tonix Pharmaceuticals Holding Corp. is more favorable than Echo Therapeutics.

Summary

Tonix Pharmaceuticals Holding Corp. beats Echo Therapeutics on 5 of the 8 factors compared between the two stocks.

Echo Therapeutics Company Profile

Echo Therapeutics, Inc. is a medical device company. The Company is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. The Company operates through the development of transdermal skin permeation and diagnostic medical devices segment. The Company has also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, enhanced delivery of topical pharmaceuticals and other applications. The CGM System includes a skin preparation device, transdermal glucose sensor, battery and wireless transmitter. The Company has conducted several human feasibility clinical studies with its CGM System in healthy subjects, diabetics and critically ill patients, as well as a clinical study at several hospitals in the United States.

Receive News & Ratings for Echo Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Echo Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.